All AbMole products are for research use only, cannot be used for human consumption.
Cabazitaxel (Jevtana) is a semi-synthetic derivative of a natural taxoid. Cabazitaxel (Jevtana) increases CYP3A enzyme activities in rat hepatocytes. The mean ex-vivo human plasma protein binding of Cabazitaxel (Jevtana) is 91.6%. Cabazitaxel (Jevtana) is rapidly and extensively metabolised into numerous metabolites. Cabazitaxel (Jevtana) demonstrates activity in several murine and human resistant cell lines. With a 4-day exposure to cabazitaxel, cytotoxicity is noted with relatively low cabazitaxel concentrations. Cabazitaxel (Jevtana) shows high antitumor activity in 3 human colorectal cell lines (HCT-116, HCT-8, and HT-29). In accompanying models, Cabazitaxel (Jevtana) has significant antitumor activity. In murine tumor xenografts (colon C38 and pancreas P03), Cabazitaxel (Jevtana) causes complete tumor regressions. Using SF-295 and U251 human glioblastoma cell lines, both orthotopic and subcutaneous murine xenografts are generated. Cabazitaxel (Jevtana) treatment leads to complete regression in the majority of subcutaneously implanted tumors. Cabazitaxel (Jevtana) has entered in a phase I clinical trial in the treatment of solid cancer. Cabazitaxel (Jevtana) plus Prednisone, Carboplatin has entered in a phase II clinical trial in the treatment of prostate cancer. Cabazitaxel is a semi-synthetic derivative of a natural taxoid.
 |
Source | Mol Pharm (2015). Figure 2. Cabazitaxel |
| Method | Plasma Pharmacokinetics | |
| Cell Lines | Abcb1a/1b-/-, Abcg2-/- and Abcb1a/1b;Abcg2-/- mice | |
| Concentrations | 10 mg/kg | |
| Incubation Time | 8 h | |
| Results | Absorption of cabazitaxel was rapid, with a Tmax occurring at or before 30 minutes in all strains. |
 |
Source | Mol Pharm (2015). Figure 1. Cabazitaxel |
| Method | Transport Assays | |
| Cell Lines | MDCK-II parental cells | |
| Concentrations | 5 μM | |
| Incubation Time | 8 h | |
| Results | In MDCKII parental cells, there was modest but significant apically directed transport of cabazitaxel, which was completely inhibited by the ABCB1 inhibitor zosuquidar, suggesting some transport by the low-level endogenous canine ABCB1. In MDCKII-hABCB1 cells. |
| Cell Experiment | |
|---|---|
| Cell lines | MCF-7 cells |
| Preparation method | Parallel drug selections were initiated using 0.1 nmol/L cabazitaxel, a concentration that would inhibit growth in MCF-7 cells by 50% (IC50 value) with and without 2 μmol/L PSC-833. Selections continued by increasing the drug concentration in a stepwise manner up to a final concentration of 5 nmol/L cabazitaxel. |
| Concentrations | 5 nmol/L |
| Incubation time | 72 h |
| Animal Experiment | |
|---|---|
| Animal models | Male nude mice |
| Formulation | 1% medium /0.1% Tween-20 |
| Dosages | 30 mg/kg |
| Administration | i.v. |
| Molecular Weight | 835.93 |
| Formula | C45H57NO14 |
| CAS Number | 183133-96-2 |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Duran GE, et al. Mol Cancer Ther. Mechanisms of resistance to cabazitaxel.
| Related Products |
|---|
| 2-Bromo-4-chlorophenylacetic acid
2-Bromo-4-chlorophenylacetic acid is a biochemical reagent. |
| CPN-351 TFA
CPN-351 TFA is a selective pentapeptide antagonist of human NMUR1 with a pA2 of 7.35. CPN-351 TFA can be used for the research of inflammation. |
| 5-Phenyluracil
5-Phenyluracil is a pyrimidine derivative, a class of heterocyclic aromatic organic compounds crucial in biochemistry. It serves as a synthetic nucleoside analogue, meaning it mimics the structure of naturally occurring nucleosides like uridine. This structural similarity allows it to participate in biochemical reactions, often interfering with normal cellular processes, making it a valuable tool in studying nucleic acid metabolism and developing antiviral and anticancer agents. |
| 7-Deoxyloganin
7-Deoxyloganin is a biosynthetic precursor of Loganin. 7-Deoxyloganin undergoes hydroxylation catalyzed by 7-deoxyloganin 7-hydroxylase, a cytochrome P450-dependent monooxygenase, to produce Loganin. |
| Mannose-BSA
Mannose-BSA is an important organic intermediate that combines the properties of mannose and bovine serum albumin, which is of unique value in the field of scientific research, and can be used as a key substance in a variety of organic synthesis reactions. Mannose is an important monosaccharide that binds specifically to mannose receptors (e.g., CD206 receptors on dendritic cells and macrophages), and therefore has a wide range of applications in immunomodulation and targeted drug delivery. BSA is a protein carrier that is commonly used for biocoupling, and its abundant surface amino groups can covalently bind to mannose to form a mannose-BSA complex. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
